To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Incyte Corp. (NASDAQ:INCY) was off $0.44 to $19.63 last week after partner Novartis AG (NYSE:NVS; SIX:NOVN) disclosed in its 2Q11 earnings that it submitted an MAA to EMA for ruxolitinib (INC424) to treat myelofibrosis. Novartis has ex-U.S. rights to the compound from Incyte, which submitted an NDA to FDA in June.

Talon Therapeutics Inc. (OTCBB:TLON) lost $0.04 to $0.96 last week after submitting an NDA to FDA for cancer candidate Marqibo vincristine sulfate. Talon is seeking accelerated approval to treat Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in patients with two or more relapses or in patients whose cancer has progressed following two or more leukemia therapies.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) was off $0.19 to $50.98 on Friday after EMA's CHMP recommended approval of Incivo

Read the full 1239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers